Dendritic cells pulsed with total tumor RNA for activation NK-like T cells against glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 75, Issue 2, 2005, Pages 111-118

  Vichchatorn, Prachya ^a   Wongkajornsilp, Adisak ^b   Petvises, Sawang ^c   Tangpradabkul, Sumalee ^a   Pakakasama, Samart ^b   Hongeng, Suradej ^a,b,d  

^a Mahidol University   (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c THAMMASAT UNIVERSITY   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Adoptive immunotherapy; Dendritic cells; Glioblastoma multiforme; NK like T cells

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; RNA; TUMOR RNA; UNCLASSIFIED DRUG;

ADOLESCENT; ADOPTIVE IMMUNOTHERAPY; ADULT; ANTIGEN PRESENTATION; ARTICLE; CHILD; COCULTURE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NATURAL KILLER T CELL; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANTIGEN PRESENTATION; ANTIGENS, CD3; ANTIGENS, CD56; CELL LINE; CELL LINE, TUMOR; COCULTURE TECHNIQUES; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GLIOBLASTOMA; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; RNA, NEOPLASM; T-LYMPHOCYTES; UMBILICAL VEINS;

EID: 29244463830     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-005-2317-2     Document Type: Article

References (32)

1. Walker MD, Alexander E, Hunt WE: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas: a cooperative trial. J Neurosurg 49: 333-343, 1978
2. Walker MD, Green SB, Byar DP, Alexander EJ, Batzdorf U, Hunt WE, MacCarty CS, Mahaley MS, Mealy JJ, Owens G, Ransahoff JI, Robertson JT, Shapiro WR, Smith KRJ, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosureas for the treatment of malignant gliomas after surgery. N Engl J Med 303: 1323-1329, 1980
3. DeAngelis LM, Burger PC, Green SB, Cairncross JG: Malignant glioma: who benefits from adjuvant chemotherapy?. Ann Neurol 44: 691-695, 1998
4. Fong L, Engleman E: Dendritic cells in cancer immunotherapy. Ann Rev Immunol 18: 767-811, 2000
5. Bell D, Young J, Banchereau J: Dendritic cells. Adv Immunol 72: 225-324, 1999
6. Milazzo C, Reichardt VL, Muller MR, Grunebach F, Brossart P: Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA. Blood 101: 997-982, 2003
7. Heiser A, Maurice MA, Yancey DR, Wu NZ, Dahm P, Pruitt SK, Boczkowski D, Nair SK, Ballo MS, Gilboa E, Vieweg J: Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J Immunol 166: 2953-2960, 2001
8. Schmitt WE, Stassar MJ, Schmitt W, Little M, Cochlovius B: In vitro induction of a bladder cancer-specific T-cell response by mRNA-transfected dendritic cells. J Cancer Res Clin Oncol 127: 203-206, 2001
9. Ashley DM, Faiola B, Nair S, Hale LP, Bigner DD, Gilboa E: Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 186: 1177-1182, 1997
10. Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E: Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 60: 1028-1034, 2000
11. + killer cells. Ann Hematol 74: 51-56, 1997
12. Schmidt RE, Murray C, Daley JF, Schlossman SF, Ritz J: A subset of natural killer cells in peripheral blood displays mature T cell phenotype. J Exp Med 164: 351-356, 1986
13. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH: The relationship of CD 16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 136: 4480-4486, 1986
14. + cells: examination of morphology, functions, T cell receptor rearrangement, and pore-forming protein expression. Cell Immunol 136: 486-495, 1991
15. + cells derived from T cells with potent in vivo antitumor activity in mice with SCID. J Immunol 153: 1678-1696, 1994
16. + T cells to Fas-mediated apoptosis. Cancer Immunol Immunother 49: 335-345, 2000
17. + cytotoxic cells from chronic myeloid leukemic patients: in vitro and in vivo efficacy in severe combined immunodeficiency disease mice. Blood 92: 3318-3327, 1998
18. + cytotoxic cells from patients with chronic lymphocytic leukemia: in vitro efficacy. Haematologica 104: 72-79, 2000
19. Schmidt-Wolf IG, Finke S, Trojaneck B, Denkena A, Lefterova P, Schwella N, Heuft HG, Prange G, Korte M, Takeya M, Dorbic T, Neubauer A, Wittig B, Huhn D: Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. Br J Cancer 81: 1009-1016, 1999
20. Valteau-Couanet D, Leboulaire C, Maincent K, Tournier M, Hartmann O, Benard J, Beaujean F, Boccaccio C, Zitvogel L, Angevin E: Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood 100: 2554-2561, 2002
21. Marten A, Renoth S, Lilienfeld-Toal Mvon, Buttgereit P, Schakowski F, Glasmacher A, Sauerbruch T, Schmidt-Wolf IG: Enhanced lytic activity of cytokine-induced killer cells against multiple myeloma cells after co-culture with idiotype-pulsed dendritic cells. Haematologica 86: 1029-1037, 2001
22. Ziske C, Marten A, Schottker B, Buttgereit P, Schakowski F, Gorschluter M, Rucker Avon, Scheffold C, Chao N, Sauerbruch T, Schmidt-Wolf IG: Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA19-9. Mol Ther 3: 54-60, 2001
23. Brossart P, Grunebach F, Stuhler G, Reichardt VL, Mohle R, Kanz L, Brugger W: Generation of functional human dendritic cells from adherent peripheral blood monocytes by CD40 ligation in the absence of granulocyte-macrophage colony-stimulating factor. Blood 92: 4238-4247, 1998
24. Schmidt-Wolf IG, Lefterova P, Johnston V, Huhn D, Blume KG, Negrin RS: Propagation of large numbers of T cells with natural killer cell markers. Br J Haematol 87: 453-458, 1994
25. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr.: Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 183: 283-287, 1996
26. Porgador A, Gliboa E: Bone marrow-generated dendritic cells pulsed with class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182: 255-260, 1995
27. Ni HT, Spellman SR, Jean WC, Hall WA, Low WC: Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial glioma. J Neuro-oncol 51: 1-9, 2001
28. Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10: 281-287, 1999
29. Gong J, Chen D, Kashiwaba M, Kufe D: Induction of antitumor activity by immunization with fusion of dendritic cell and carcinoma cells. Nat Med 3: 558-561, 1997
30. Kim KD, Choi SC, Kim A, Choe YK, Choe IS, Lim JS: Dendritic cell-tumor coculturing vaccine can induce antitumor immunity through both NK and CTL interaction. Int Immunopharmacol 1: 2117-2129, 2001
31. Schmidt J, Eisold S, Buchler MW, Marten A: Dendritic cells reduce number and function of CD4(+)CD25(+) cells in cytokine-induced killer cells derived from patients with pancreatic carcinoma. Cancer Immunol Immunother 253: 1018-1026, 2004
32. + T cells responding to serologically defined autoantigens suppress antitumor immune responses. Proc Natl Acad Sci USA 100: 10902-10906, 2003